Back to Search
Start Over
The Use of Benzodiazepine Receptor Agonists and the Risk of Hospitalization for Pneumonia
- Source :
- Chest. 153:161-171
- Publication Year :
- 2018
- Publisher :
- Elsevier BV, 2018.
-
Abstract
- Background The relationship between the use of benzodiazepine-receptor agonists (BZRAs) and the risk of hospitalization for pneumonia remains inconclusive. This study aimed to explore the association between BZRA use and hospitalization for pneumonia in a general population. Methods This population-based nested case-control study used Taiwan's National Health Insurance Research Database between 2002 and 2012. We included only new users who did not have any BZRA prescriptions on record in the preceding 2 years and identified 12,002 subjects who were hospitalized for pneumonia (International Classification of Diseases, Ninth Revision codes 480-486, and 507) and 12,002 disease risk score-matched control subjects. A logistic regression model was used to determine the association of BZRA use and hospitalization for pneumonia. The exposure date, dose-response relationship, and class of BZRAs were comprehensively assessed. Results Current BZRA exposure was associated with hospitalization for pneumonia (adjusted OR [aOR],1.86; 95% CI, 1.75-1.97). Benzodiazepine hypnotic agents (aOR, 2.42; 95% CI, 2.16-2.71) had a higher risk of pneumonia than did benzodiazepine anxiolytic agents (aOR, 1.53; 95% CI, 1.44-1.63) or nonbenzodiazepine hypnotic agents (aOR, 1.60; 95% CI, 1.46-1.76). The pneumonia risk was increased with ultrashort-acting and short- to intermediate-acting agents, a higher defined daily dose, and the number of BZRAs used. Among individual BZRAs examined, midazolam had a higher risk (aOR, 5.77; 95% CI, 4.31-7.73) of hospitalization for pneumonia than did the others. Conclusions This study suggests that there is a dose-response relationship between current BZRA use and the risk of hospitalization for pneumonia. In addition, benzodiazepine hypnotic agents, especially midazolam, present a greater risk of hospitalization for pneumonia. These findings reinforce the importance of a careful analysis of the benefits vs the risks of BZRA use.
- Subjects :
- Pulmonary and Respiratory Medicine
medicine.medical_specialty
education.field_of_study
Benzodiazepine
business.industry
medicine.drug_class
Population
Nonbenzodiazepine
Critical Care and Intensive Care Medicine
medicine.disease
Logistic regression
03 medical and health sciences
Pneumonia
0302 clinical medicine
Defined daily dose
Emergency medicine
Nested case-control study
medicine
030212 general & internal medicine
Medical prescription
Cardiology and Cardiovascular Medicine
Intensive care medicine
business
education
030217 neurology & neurosurgery
Subjects
Details
- ISSN :
- 00123692
- Volume :
- 153
- Database :
- OpenAIRE
- Journal :
- Chest
- Accession number :
- edsair.doi...........605246727cdf8fcaae9924d3f52d04cb
- Full Text :
- https://doi.org/10.1016/j.chest.2017.07.030